(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） （Stock Code 股份代號：1069） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, Date as postmarked China Health Technology Group Holding Company Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.01069.com.cn and the website of The Stock Exchan ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） （Stock Code 股份代號：1069） NOTIFICATION LETTER 通知信函 Dear Non-registered Holder(s) (Note 1) , Date as postmarked China Health Technology Group Holding Company Limited (the "Company") - Notification of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.01069.com.cn and the website of The ...

Revenue Generation - The group generated revenue of approximately RMB 7,100,000 from the sale of 5,250 cubic meters of timber during the reporting period [10]. - Ginseng sales revenue amounted to approximately RMB 16,800,000, including RMB 8,850,000 from purchased ginseng and RMB 7,950,000 from self-cultivated ginseng [12]. - The health products business recorded revenue of approximately RMB 10,500,000 during the reporting period [13]. - The company recorded revenue of approximately RMB 34,400,000 during the reporting period, an increase from RMB 31,100,000 in the previous period [16]. - Revenue for the six months ended December 31, 2025, was RMB 34,393,000, an increase of 10.3% from RMB 31,112,000 in the same period of 2024 [51]. - Total revenue for the six months ended December 31, 2025, was RMB 34,393,000, an increase from RMB 31,112,000 for the same period in 2024, representing a growth of approximately 7.3% [63]. - The revenue from the forestry business was RMB 7,068,000, while the ginseng business generated RMB 16,776,000 [69]. - For the six months ended December 31, 2024, total revenue was RMB 31,112,000, with a profit of RMB 4,978,000, indicating a year-over-year increase in revenue [71]. Profit and Expenses - Gross profit for the period was approximately RMB 4,100,000, up from RMB 2,800,000 in the prior period [17]. - Selling and distribution expenses increased to RMB 499,000 from RMB 148,000, primarily due to advertising costs [18]. - Administrative expenses decreased by approximately 9.8% to RMB 8,500,000 from RMB 9,400,000 in the previous period, mainly due to a reduction in legal and professional fees [19]. - Other income was approximately RMB 11,500,000, down from RMB 13,100,000, with net gains from changes in fair value of artificial forest assets contributing approximately RMB 7,100,000 [20]. - Financing costs increased to RMB 1,800,000 from RMB 1,300,000, attributed to interest on bills payable [21]. - The company recorded a profit of approximately RMB 5,300,000, compared to RMB 5,000,000 in the previous period, with total comprehensive income attributable to owners of RMB 5,400,000, down from RMB 6,400,000 [22]. - Profit before tax for the six months was RMB 5,256,000, slightly up from RMB 5,042,000 in the previous year [51]. - Net profit for the period was RMB 5,252,000, compared to RMB 4,978,000 in 2024, reflecting a year-on-year increase of 5.5% [51]. - Total comprehensive income for the period was RMB 5,406,000, compared to RMB 6,353,000 in 2024 [51]. Assets and Liabilities - As of December 31, 2025, the company had total assets of approximately RMB 201,300,000 and net assets of approximately RMB 56,900,000, with cash and bank balances of approximately RMB 2,600,000 [23]. - The capital debt ratio as of December 31, 2025, was approximately 71.7%, down from 77.3% as of June 30, 2025 [27]. - Non-current assets totaled RMB 160,940,000 as of December 31, 2025, compared to RMB 145,376,000 as of June 30, 2025, reflecting an increase of approximately 10.7% [52]. - Current liabilities decreased to RMB 30,075,000 as of December 31, 2025, from RMB 43,073,000 as of June 30, 2025, indicating a reduction of about 30.2% [52]. - The company's total equity increased to RMB 56,886,000 as of December 31, 2025, up from RMB 46,720,000 as of June 30, 2025, marking a growth of approximately 21.5% [53]. - The total assets as of December 31, 2025, were RMB 201,318,000, a slight decrease from RMB 205,417,000 as of June 30, 2025 [72]. - The total liabilities decreased from RMB 158,697,000 as of June 30, 2025, to RMB 144,432,000 as of December 31, 2025 [72]. Share Capital and Financing - The company announced a placement of up to 17,000,000 new shares at a price of HKD 0.28 per share, aiming to raise approximately HKD 4,630,000 for general working capital [33]. - The company has issued and paid-up ordinary shares totaling 102,924,000 shares, with a par value of HKD 0.1 per share [98]. - The company underwent a share restructuring, resulting in a reduction of 9,000,000 shares on July 1, 2025 [98]. - The company raised HKD 1,700,000 through the placement of new shares during the reporting period [98]. - The book value of the issued shares as of December 31, 2025, is RMB 9,406,000 [98]. Ginseng and Health Products - The group has initiated ginseng cultivation on its forest land, with the first phase involving the planting of approximately 6 million ginseng plants [11]. - The group plans to gradually reduce reliance on suppliers for aged ginseng as it builds sufficient inventory of its own [14]. - The group has established a long-term supply framework agreement with suppliers to ensure a stable supply of aged ginseng [12]. - The group aims to expand its health products market into China in the future [14]. - The group has expanded its business into health product manufacturing and trade, opening a 150 square meter store in Hong Kong [13]. Environmental and Regulatory Risks - The group faces regulatory and environmental risks and has established environmental policies to comply with local laws [89]. - The group's revenue depends on sufficient timber harvesting capacity, which may be affected by climate and natural disasters [90]. - The group must contend with risks related to fluctuations in timber prices and sales volumes, with management conducting regular industry trend analyses to control this risk [91]. Inventory and Receivables - As of December 31, 2025, trade receivables amounted to RMB 24,442,000, a decrease of approximately 27.8% from RMB 33,796,000 as of June 30, 2025 [93]. - As of December 31, 2025, trade payables were RMB 2,493,000, down approximately 55.1% from RMB 5,535,000 as of June 30, 2025 [94]. - The inventory increased significantly to RMB 5,987,000 as of December 31, 2025, from RMB 1,480,000 as of June 30, 2025, representing a growth of approximately 303.4% [52].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股份代號：1069） (1)建議按於記錄日期每持有一(1)股現有股份獲發 兩(2)股供股股份之基準進行非包銷供股；及 (2)就供股配售配售股份 本公司配售代理 1 建議供股 本公司建議以供股方式，按認購價每股供股股份0.25港元，基於合資格股東於記 錄日期營業時間結束時每持有一股(1)股現有股份獲發兩(2)股供股股份之基準， 發行最多205,848,440股供股股份（假設於記錄日期或之前已發行股份數目並無 變動），籌集所得款項總額最多約51.5百萬港元（假設供股獲悉數認購）。 假設於記錄日期或之前已發行股份數目並無變動及供股獲悉數認購，供股所得 款項淨額上限（經扣除估計開支約1.5百萬港元後）預期約為50.0百萬港元。所得 款項用途詳情載於本公告「供股之理由及裨益以及所得款項用 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國健康科技集團控股有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01069 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 10 ...

Group 1 - The core viewpoint of the article is that China Health Technology Group (01069) reported a revenue of RMB 34.393 million for the six months ending December 31, 2025, representing a year-on-year growth of 10.55% [1] - The net profit for the same period was RMB 5.252 million, which reflects a year-on-year increase of 5.5% [1] - The earnings per share (EPS) for the company stood at 5.25 cents [1]

Group 1 - The core viewpoint of the article is that China Health Technology Group (01069) reported its interim results for the six months ending December 31, 2025, showing a revenue of RMB 34.393 million, which represents a year-on-year increase of 10.55% [1] - The net profit for the same period was RMB 5.252 million, reflecting a year-on-year growth of 5.5% [1] - The earnings per share (EPS) for the company stood at 5.25 cents [1]

Financial Performance - The company's revenue for the six months ended December 31, 2025, was RMB 34,393,000, an increase of 10.3% compared to RMB 31,112,000 for the same period in 2024[4] - Gross profit for the same period was RMB 4,137,000, representing a gross margin of approximately 12.0%, up from RMB 2,777,000 in the previous year[4] - The company reported a profit before tax of RMB 5,256,000, slightly up from RMB 5,042,000 in the prior period, indicating a growth of 4.3%[4] - Net profit for the period was RMB 5,252,000, compared to RMB 4,978,000 in the previous year, reflecting an increase of 5.5%[4] - Total revenue for the six months ended December 31, 2025, was RMB 34,393,000, a decrease from RMB 31,112,000 for the same period in 2024, representing a decline of approximately 10.5%[18] - The gross profit for the six months ended December 31, 2025, was RMB 9,401,000, compared to RMB 11,364,000 for the same period in 2024, indicating a decrease of about 17.3%[18] - The net profit for the six months ended December 31, 2025, was RMB 5,252,000, down from RMB 4,978,000 in 2024, reflecting a decline of approximately 5.5%[26] - The group reported a profit of approximately RMB 5,300,000 for the period, compared to RMB 5,000,000 in the previous period, with total comprehensive income attributable to shareholders at RMB 5,400,000, down from RMB 6,400,000[46] Assets and Liabilities - Total assets as of December 31, 2025, were RMB 171,243,000, an increase from RMB 162,344,000 as of June 30, 2025[5] - The total assets as of December 31, 2025, amounted to RMB 201,318,000, a slight decrease from RMB 205,417,000 as of June 30, 2025[19] - The total liabilities as of December 31, 2025, were RMB 144,432,000, down from RMB 158,697,000 as of June 30, 2025, showing a reduction of about 8.9%[19] - The company’s total equity rose to RMB 56,886,000 from RMB 46,720,000, showing a growth of 21.7%[6] - As of December 31, 2025, the group had total assets valued at approximately RMB 201,300,000 and net assets of approximately RMB 56,900,000, with cash and bank balances of approximately RMB 2,600,000[47] - The capital debt ratio as of December 31, 2025, was approximately 71.7%, a decrease from 77.3% as of June 30, 2025[51] Business Operations - The company is engaged in forestry management, ginseng cultivation and trade, and health product trade, indicating a diversified business model[7] - The company plans to continue its focus on expanding its health product offerings and enhancing its operational efficiency[7] - The company successfully harvested and sold approximately 5,250 cubic meters of timber, generating revenue of about RMB 7,100,000 during the reporting period[36] - Ginseng business revenue amounted to approximately RMB 16,800,000, including RMB 8,850,000 from purchased ginseng and RMB 7,950,000 from self-cultivated ginseng[37] - The health products business generated revenue of approximately RMB 10,500,000 during the reporting period[38] Expenses and Income - Sales and distribution expenses increased to RMB 499,000 from RMB 148,000 in the previous period, primarily due to advertising costs[42] - Administrative expenses decreased by approximately 9.8% to RMB 8,500,000 from RMB 9,400,000 in the previous period, mainly due to a reduction in legal and professional fees[43] - The group recorded other income of approximately RMB 11,500,000 during the reporting period, compared to RMB 13,100,000 in the previous period, primarily from the fair value changes of artificial forest assets[44] - Financing costs for the six months ended December 31, 2025, were RMB 1,798,000, compared to RMB 1,337,000 in the same period of 2024, representing an increase of about 34.5%[20] - Financing costs amounted to RMB 1,800,000, an increase from RMB 1,300,000 in the previous period, due to interest on bills payable[45] Shareholder Information - The company did not declare or propose any dividends for the six months ended December 31, 2025, consistent with the previous period[24] - No interim dividend was recommended for the reporting period, consistent with the previous period[60] - The total number of issued ordinary shares as of December 31, 2025, was 102,924,220 shares, down from 859,242,204 shares as of June 30, 2025[52] - The company announced a placement of up to 17,000,000 new shares at a price of HKD 0.28 per share, aiming to raise approximately HKD 4,630,000 for general working capital[57] Audit and Compliance - The audit committee has been established in accordance with the rules set out in Appendix C1 of the listing rules, consisting of three independent non-executive directors[67] - The group's unaudited interim financial statements have been reviewed by the audit committee[68] - The interim results announcement will be published on the Hong Kong Stock Exchange website and the company's website, containing all required information as per listing rules[69] Inventory and Receivables - Inventory levels increased significantly to RMB 5,987,000 from RMB 1,480,000, indicating a strategic buildup of stock[5] - The average credit period for trade receivables is 120 days, with trade receivables totaling RMB 24,442,000 as of December 31, 2025, down from RMB 33,796,000 as of June 30, 2025[13] - Trade payables amounted to RMB 27,962,000 as of December 31, 2025, compared to RMB 29,029,000 as of June 30, 2025[14] Future Outlook - The company has obtained a harvesting permit for 2026, allowing for the same harvesting volume of 5,250 cubic meters as in 2025[39] - The group has no significant contingent liabilities as of December 31, 2025[49]

Group 1 - The company, China Health Technology Group (01069.HK), announced a board meeting scheduled for February 27, 2026, to consider and approve the interim results announcement for the six months ending December 31, 2025 [1] - The board will also consider the proposal for an interim dividend payment, if applicable [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股份代號：1069） 董事會會議日期 承董事會命 中國健康科技集團控股有限公司 主席兼執行董事 畢雪 香港，二零二六年二月十二日 於本公告日期，董事會成員包括執行董事畢雪女士及曹喜瑩女士；及獨立非執行 董事周穎楠先生、劉淑華女士及李良杰先生。 中國健康科技集團控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董 事會（「董事會」）謹此宣佈，將於二零二六年二月二十七日（星期五）舉行董事會 會議，以（其中包括）考慮及批准本集團截至二零二五年十二月三十一日止六個月 的中期業績公告，以及考慮建議派付中期股息（如有）。 ...